Details of the Drug Combination

General Information of Drug Combination (ID: DC1WWR0)

Drug Combination Name
BIO-300 Rufinamide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs BIO-300   DMJ7NVI Rufinamide   DMWE60C
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 3.22
Bliss Independence Score: 3.22
Loewe Additivity Score: 3.58
LHighest Single Agent (HSA) Score: 3.6

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Rufinamide
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved (orphan drug) [4]
Pediatric lennox-gastaut syndrome 8A62.1 Approved [5]
Seizure disorder 8A6Z Approved [4]
Rufinamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [6]
------------------------------------------------------------------------------------
Rufinamide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [7]
Carboxylesterase 2 (CES2) DETHCPD EST2_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7470).
5 Clinical pipeline report, company report or official report of Eisai.
6 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
7 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.